Announced details
Commercial manufacturing of regenerative medicine products for pleural mesothelioma; regenerative, cellular and gene therapies
Akatsuki Therapeutics is the Company’s development partner and leads the development of AKT-01/HLCN061. The Company and Akatsuki Therapeutics are jointly advancing development. The Company’s relationship with AMED is that the project was selected as a supported research project under this program.
AMED is a National Research and Development Agency. Akatsuki Therapeutics is a biotechnology company headquartered at 8-1 Kakuda-cho, Kita-ku, Osaka, Osaka Prefecture. Its representative director is Yamazaki Junya (山﨑順也). The company develops next-generation cellular immunotherapies for cancer and other serious diseases.
50 L bioreactor
The project currently has no impact on the consolidated results for the fiscal year ending December 2026. The Company will promptly disclose any matters requiring disclosure that arise in the future.
The company does not address Contract Value / Offering price.
AMED (Japan Agency for Medical Research and Development) FY2026 open call information
| Item | Details |
|---|---|
| Names of Products / Services Covered | eNK® cells, AKT-01/HLCN061 (NK cells derived from genetically modified iPS cells) |
| Counterparty | Japan Agency for Medical Research and Development (AMED), Akatsuki Therapeutics |
| Counterparty overview | AMED is a National Research and Development Agency. Akatsuki Therapeutics is a biotechnology company headquartered at 8-1 Kakuda-cho, Kita-ku, Osaka, Osaka Prefecture. Its representative director is Yamazaki Junya (山﨑順也). The company develops next-generation cellular immunotherapies for cancer and other serious diseases. |
| Relationship with the Company | Akatsuki Therapeutics is the Company’s development partner and leads the development of AKT-01/HLCN061. The Company and Akatsuki Therapeutics are jointly advancing development. The Company’s relationship with AMED is that the project was selected as a supported research project under this program. |
| Applicable area | Commercial manufacturing of regenerative medicine products for pleural mesothelioma; regenerative, cellular and gene therapies |
| Location scale | 50 L bioreactor |
| Impact on Business Performance | The project currently has no impact on the consolidated results for the fiscal year ending December 2026. The Company will promptly disclose any matters requiring disclosure that arise in the future. |
| Source | AMED (Japan Agency for Medical Research and Development) FY2026 open call information |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.AMED provides funding for establishing the quality and manufacturing methods required at the preclinical stage to advance to company-sponsored clinical trials, with the aim of promoting the commercialization of regenerative medicine products and other products in the fields of regenerative, cellular and gene therapies.